AVITA Medical Secures Critical BARDA Contract, Potential Value Up to $25.5 Million

AVITA Medical has secured a significant contract from the Biomedical Advanced Research and Development Authority (BARDA), a key U.S. government agency for public health emergency preparedness. The award, which carries a potential total value of up to $25.5 million, marks a strategic win for the regenerative medicine company. This funding is specifically designated to support the development and potential procurement of AVITA's RECELL® System for thermal burn injuries, signaling strong federal confidence in the technology's role in national health security.

The contract structure includes an initial commitment of $12.75 million, with the remaining funds contingent on the achievement of specific development and procurement milestones. This milestone-based approach ties government funding directly to tangible progress, a common BARDA mechanism that manages taxpayer risk while driving focused execution. The RECELL® System, which uses a patient's own skin cells to treat severe burns, is positioned as a critical countermeasure for mass casualty incidents involving burn injuries.

This award places AVITA Medical within a select group of companies backed by BARDA's deep resources and strategic stockpiling initiatives. Successfully meeting the contract milestones could lead to the inclusion of the RECELL® System in the U.S. Strategic National Stockpile, creating a substantial, long-term government customer. The deal not only provides non-dilutive capital to advance the technology but also validates its importance in the federal government's disaster response and biodefense planning, potentially opening doors to broader adoption and commercial expansion.